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Recent advancements in imaging diagnostics have focused on the use of nanostructures that entrap 
Magnetic Resonance Imaging (MRI) Contrast Agents (CAs), without the need to chemically modify 
the clinically approved compounds. Nevertheless, the exploitation of microfluidic platforms for 
their controlled and continuous production is still missing. Here, a microfluidic platform is used to 
synthesize crosslinked Hyaluronic Acid NanoParticles (cHANPs) in which a clinically relevant MRI-CAs, 
gadolinium diethylenetriamine penta-acetic acid (Gd-DTPA), is entrapped. This microfluidic process 
facilitates a high degree of control over particle synthesis, enabling the production of monodisperse 
particles as small as 35 nm. Furthermore, the interference of Gd-DTPA during polymer precipitation is 
overcome by finely tuning process parameters and leveraging the use of hydrophilic-lipophilic balance 
(HLB) of surfactants and pH conditions. For both production strategies proposed to design Gd-loaded 
cHANPs, a boosting of the relaxation rate T1 is observed since a T1 of 1562 is achieved with a 10 μM 
of Gd-loaded cHANPs while a similar value is reached with 100 μM of the relevant clinical Gd-DTPA in 
solution. The advanced microfluidic platform to synthesize intravascularly-injectable and completely 
biocompatible hydrogel nanoparticles entrapping clinically approved CAs enables the implementation 
of straightforward and scalable strategies in diagnostics and therapy applications.
The Magnetic Resonance Imaging (MRI) represents the first-line diagnostic imaging modality for numerous 
indications. It is a clinically well-established, non-invasive technique that leverages the magnetic properties of 
water protons present in the body to produce three-dimensional whole body anatomical and functional images1,2.
High magnetic fields (1.5 T and above) are clinically favoured because of their higher signal-to-noise 
ratio, capability for MR spectroscopy3 and other forms of functional MRI, such as high-speed imaging and 
high-resolution imaging. MRI signal intensity is related to the relaxation rate of in vivo water protons and can be 
enhanced by the administration of a contrast agent (CA) prior to scanning. These CAs utilize paramagnetic metal 
ions to enhance the contrast in an MR image by positively influencing the relaxation rates of water protons in the 
immediate surroundings of the tissue in which they localize. The ability of CAs to effectively enhance image con-
trast depends on their relaxivity (longitudinal r1; transversal r2) and the level of accumulation at the target site4.
Among different CAs, Gadolinium-based ones, used in up to 30% of clinical MRI scans5, consist of poly- 
amino carboxylate complexes of Gd ions, where Gd ions cytotoxicity is sequestered via chelation with lig-
ands such as diethylenetriaminepentaacetic acid (DTPA) and tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA)6–8. However, despite its certain role, Gadolinium-based CAs, like most of other clinically relevant CAs, 
suffer from poor sensitivity6 and rapid renal clearance, requiring long scan times, thus severely limiting the time 
window for MRI. In addition, they present low tissue specificity, leading to concerns in linking the use of these 
CAs with nephrogenic systemic fibrosis (NSF)9 and progressive accumulation in various central nervous system 
(CNS) structures following repeated gadolinium administration10.
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To date, several efforts have increased tissue specificity, thus reducing nephrotoxicity, by designing architec-
tures that entrap or conjugate CAs11–20. Recently, approaches using batch conventional synthesis were shown to 
successfully boost relaxivity by entrapping Gd-based CAs into biocompatible matrices, without chemically mod-
ifying the clinically approved Gd-chelates21–23. Decuzzi et al.4 optimized the performance of MRI nanoconstructs 
by confining Gd-DTPA within porous structures of silicon microparticles (about 1–2 μ m) produced by microfab-
rication. They examined the consequences of geometrical confinement of CAs within the nanopores, achieving 
a 2–3 times enhancement in r1 without chemical modification of the chelate; however, a considerable increase 
of the relaxometric properties was observed only when nanotubes or fullerenes were also incorporated into the 
silicon structure. Courant et al. enhanced relaxivity by encapsulating Gd-chelates (Gd-DOTA) into hydrophilic 
and biocompatible polymer nanoparticles (about 250 nm) obtained by the ionotropic gelation between Chitosan 
(CH) and Hyaluronic Acid (HA)24.
Recently, we have exploited the impact of crosslinked and un-crosslinked biopolymer matrices on relaxo-
metric properties of CAs where the contribution to the enhancement of CAs is highlighted and attributed to the 
reduced mobility of water within the hydrogel25. However, systems with nanometric and monodisperse size under 
100 nm are likely to improve delivery functions26 to the tissues, stability of the metal chelates, and also provide 
enhanced relaxometric properties of the Gadolinium-based CAs.
Nanoprecipitation represents a very promising and powerful approach to produce biopolymeric nanoparticles 
in batch processes27 even if polydispersity due to aggregation effects challenges in the complete removal of the 
solvents, in particular for high polymer–solvent affinities, and low loadings of hydrophilic compounds28. Indeed, 
the inherent variability and complexity of conventional batch precipitation processes often make it problematic 
to produce particles with well-defined physicochemical and functional attributes27,29.
To address these demands, a microfluidic platform is presenting as an ideal method to tightly control the final 
particle properties, i.e. size, polydispersity, etc., due to the process’s ability to accurately control process parame-
ters and thus enables efficient, continuous and tunable mixing30–36.
Over the past decade, microfluidics has enabled the production of a variety of enhanced nanoparticles for 
applications in therapy and diagnostics37–47. Recently, Karnik et al.36 synthesized PLGA-PEG nanoparticles in a 
microfluidic channel by rapidly mixing polymer-acetonitrile solutions and water using hydrodynamic flow focus-
ing, in a controlled nanoprecipitation process. Valencia et al.48 developed homogeneous lipid_Quantum Dots 
(QDs) NanoParticles (NPs) composed of CdSe/ZnS QDs coated with a lecithin and DSPE-PEG layer. Capretto 
et al.49 investigated the production of polymer micelles (PMs) using Pluronic tri-block copolymer in a series of 
microfluidic-based reactors with a hydrodynamic flow focusing configuration. Their results showed that the PM’s 
size was determined by the flow rate ratio, the device geometry, viscosity and fluidic conditions. Souza Bicudo et al.50  
described a process for the production of Hyaluronic Acid (HA) crosslinked nanoparticles by nanoprecipita-
tion at the interface of organic solvent/water phases. HA nanoparticles were crosslinked with adipic dihydrazide 
(ADH) and chloride carbodiimide (EDCL) and presented sizes ranging from 140 to 460 nm, depending on the 
operating conditions. However, although great efforts have been made to apply microfluidic technologies to the 
production of nanoparticles, the exploitation of microfluidic approaches to support the design of nanostructures 
to improve relaxometric properties of clinically approved CAs for MRI has not been developed.
Here, the presented microfluidic platform takes advantage of interferences caused by the presence of 
Gd-DTPA in flow-focused nanoprecipitation, enabling the formation of monodisperse crosslinked Hyaluronic 
Acid Nanoparticles (cHANPs) under 100 nm, which are able to impact relaxation rates of Gd-DTPA. Through 
microfluidics, we aim to achieve a fine-tuning of the mixing process among all species and thus, tight control 
of their nanoprecipitation behaviour, crosslinking reaction and the relaxometric properties. The proposed 
approach has the goal to introduce microfluidic strategies to modulate the nanoprecipitation playing on the 
hydrophilic-lipophilic properties of the surfactants or the pH solution conditions to optimize relaxometric 
performances.
Results
Successful conditions to produce cHANPs for MRI through a Microfluidic Flow-Focusing plat-
form. In flow-focused nanoprecipitation40,49,51, the non-solvent phase, flowing through two side channels, 
focuses the solvent phase in the main channel inducing the mutual diffusion of all solvents and promoting the 
precipitation of the solute and, therefore, the production of nanoparticle morphologies.
In the synthesis of cHANPs, the solvent phase consists of a hydrogel aqueous solution while the non-solvent 
phase is mainly represented by the organic solvents, i.e. acetone or ethanol, plus other compounds to improve 
or stabilize the nanoparticles (Fig. 1a and Supplementary Figure S1). Flow rate conditions play a key role and 
are evaluated by analyzing the z- Average and Polydispersity Index (PDI) values obtained by Dynamic Light 
Scattering (DLS). Results are presented in terms of the Flow Rate Ratio FR2 (defined as the ratio of Volume Flow 
Rate Solvent and Volume Flow Rate Non-Solvent), and, on the dependence of FR2 ranging from 0.2 to 0.6, nano-
particle size varies from 35 nm to 500 nm (for further details see Supplementary Table S1, Figure S2). High yield 
process parameters facilitate rapid solvent extraction that promotes fast nucleation (at the expenses of growth 
rate), leading to the production of almost monodisperse nanoparticles. Relatively monodisperse nanoparticles are 
obtained even for all FR2 lower than 0.4 (Supplementary Table S1). Furthermore, Hyaluronic Acid concentration 
(CHA) also affects the nanoprecipitation, and most of our experiments are conducted at a constant CHA, 0.05% 
wt/v, allowing a longer stability of the system. However, the value of FR2 of 0.3 (obtained at 30 μ L/min -solvent 
flow rate – and 100 μ L/min – non-solvent flow rate) and CHA of 0.05% wt/v are considered as “standard flow con-
ditions” for all the experiments (Supplementary Figure S3a and b).
We next investigate the role of HA/CA ratio on the effectiveness of microfluidic mixing observing the obtained 
morphologies in the absence of the crosslinking reaction (Supplementary Figure S4). A strong influence of 
Gd-DTPA on the focused stream and, therefore, on the precipitation is observed, which induces a significant 
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increase in the nanoparticle’s size and their uncontrolled shape. Further investigations are required to address 
this behaviour towards the control of the hydrogel nanoparticles (Supplementary Figure S5). Therefore, the for-
mulation of rational crosslinking strategies is needed to control the nanoprecipitation and stability of cHANPs in 
the presence of Gd-DTPA. In this perspective, Divinyl Sulfone (DVS) has been selected among different highly 
reactive crosslinking agents for HA. Indeed, the biocompatibility of the HA-DVS, i.e. sulfonyl bis-ethyl linkages 
between the hydroxyl groups of the polymer chains (Fig. 1b), has extensively been confirmed by histological 
analysis52, making our cHANPs appropriate for the potential clinical application.
Crosslinking and Swelling behaviour of cHANPs. In the presence of Gd-DTPA, while nanoprecipita-
tion occurs, two different crosslinking strategies are exploited to perform a simultaneous reaction: the injection 
of DVS into the middle channel or the side channels (Fig. 1c and d, Supplementary Figure S6). These rational 
strategies are discussed in term of concentration and role played by pH and HLB of selected surfactants (i.e. Span 
80, Tween 21 and 85), used to avoid swelling, support the streams during the focusing action and modulate the 
nanoprecipitation.
In the first approach, Temperature is also strictly controlled to avoid the onset of the crosslinking reaction in 
the HA aqueous solution before precipitation happens. During injection into the microfluidic device, the polymer 
solution within the syringe is kept constant at 5 °C while the device is heated at 35 °C, to promote the reaction at 
the nozzle section, where the mixing takes place. In this approach, nanoparticles as small as 70 nm are produced 
at DVS concentrations of 0.6–0.8% v/v at previously defined “standard flow conditions” and CSpan80 0.5% v/v 
(Fig. 2a, time point at zero seconds). A comprehensive summary of the effects of the Temperature and surfactants 
on the flow-focusing behaviors are reported in the Supplementary Figure S7 and Table S2.
In the second approach, smaller nanoparticles of about 40 nm are formed, at the “standard flow conditions” 
and pH equal to 12.3, by adding DVS up to 4% v/v to the side channels (Fig. 2b, time point at zero seconds). 
Several experiments are also performed by adding surfactants simultaneously with DVS to the side channels, 
but in this last case, both the morphologies and the crosslinking reaction result entirely compromised. Both our 
chosen crosslinking approaches have the advantage to be highly tunable through process parameters and temper-
ature. In our system, the competition between crosslinking reaction and water extraction could mainly affect the 
Figure 1. Schematic illustration of Microfluidic experimental set-up. (a) Optical Fluorescence Microscopy 
Image of Flow-Focusing pattern; (b) Crosslinking reaction of HA hydroxyl groups with divinyl sulfone (DVS). 
Qualitative Illustration of two different crosslinking strategies processed in our microfluidic device: (c) when 
DVS is added into the middle channel; (d) when DVS is added into the side channels.
www.nature.com/scientificreports/
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second strategy, where an additional barrier to the reaction is represented by DVS diffusion from the side flows 
to the main one.
Differences in the crosslinking degree of the nanoparticles are evaluated by the swelling behaviour under 
physiological conditions for both proposed strategies. In the first strategy, a lower amount of crosslinker is used 
to reduce the swelling behaviour even after several hours. Indeed, stable nanoparticles are obtained for CDVS 
ranging from 0.8 to 1.2% v/v. The increase of CDVS at more than 1.2% v/v, however, promotes an instability of 
the flow or compromises the crosslinking reaction and, consequently, the swelling (Fig. 2a and c). Compared to 
the first approach, for the other one, a higher amount of agent is added to avoid a rapid swelling behaviour of 
nanoparticles in water. In particular, for CDVS ranging from 4 to 4.5% v/v, the swelling behaviour of the cHANPs 
is not observed even after several days. Higher or lower concentrations of DVS lead to the formation of swelling 
particles or flow instability (Fig. 2b and d). Once again, the comparison between the two proposed strategies 
highlights considerable differences in the nanoparticle behaviour. Indeed, the smaller size and the absence of 
swelling behaviour obtained in the first strategy can be related to a faster and efficient crosslinking reaction due to 
more favourable reaction conditions in the aqueous environment, an ideal pH and temperature able to promote 
a faster crosslinking among the polymer chains. Additional data at higher concentration of DVS, resulting in 
agglomeration and undefined morphologies or absence of nanoparticle formation, are not reported.
Loading Capability, Encapsulation Efficiency and Surface properties of Gd-loaded cHANPs. 
The proposed strategies also have the capability to increase or control the encapsulation efficiency (EE) in the 
cHANPs, to prevent the waste of expensive compounds and sustain their dosage over an extended treatment 
period. Results show that a DVS concentration added to the middle or the side phase has a significant impact on 
the entrapment efficiency of cHANPs. In details, for DVS in the middle channel, it is observed that an increase in 
DVS concentration (from 0.6 to 1% v/v) results in a rise of cHANPs encapsulation efficiency from 27 to 89% and a 
loading capability from 22 to 59%. On the contrary, a worse control is observed by increasing the concentration of 
Figure 2. Study of the Swelling behavior. Swelling behavior regarding nanoparticles size observed at several 
time points for different CDVS when (a) DVS is added in the middle channel, at standard process conditions, 
CSpan80 of 0.5% v/v and 35 °C; and (b) DVS is added in the side channels, at pH equal to 12.3. FE-SEM images of 
cHANPs in water at the time zero when (c) 0.8% v/v of DVS is added in the middle channel; (d) 4% v/v of DVS 
is added in the side channels.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:37906 | DOI: 10.1038/srep37906
DVS in the non-solvent phase, where a slight increase in cHANPs encapsulation efficiency and loading capability 
is obtained from 39 to 53% and from 26 to 35%, respectively, for selected DVS values of 4 and 4.5% v/v. Loading 
capability (LC) is only reported for stable nanoparticles in water and it is also compared with loading capability 
resulting by the encapsulation of a highly toxic and non-chelate Gadolinium, GdCl3 at equal conditions, proving 
that values reached are of about 90% (see the specific paragraph in Supplementary Information). The importance 
of a high encapsulation efficiency has been already emphasized since a large nanoparticles recovery is required for 
reducing manufacturing costs while size and morphology are important for quality control and biodistribution 
of injectable products. Furthermore, surface properties analysis of the empty cHANPs or cHANPs containing 
Gd-DTPA is conducted to assess the promising delivery functions of the cHANPs. Gd-free cHANPs have a neg-
ative surface charge of − 50 mV (± 4.5 mV) which can be attributed to the presence of carboxylic end groups of 
the polymer on the nanoparticle surface, proposing their availability to future decorations of the nanoparticles. 
Zeta Potential measurements show a significant increase to − 36.4 mV (± 3.01) linked to the encapsulation of 
Gd-DTPA26.
In vitro MRI. The relaxation time values of Gd-DTPA and cHANPs are calculated at 37 °C and 1.5 T. A nota-
ble change in relaxation rate is found for CDVS at 4% v/v in the side channels and at 0.8% v/v in the middle 
channel. Comparison between the relaxation time distributions of loaded cHANPs, at the same concentration 
of Gd-DTPA in HA solution, is reported in Fig. 3. Results clearly show that the relaxation time for Gd-DTPA 
entrapped within cHANPs is shorter than that of the “free” contrast agent. By tuning the process parameters and 
adjusting the crosslinking reaction, a T1 of 1562 ms is achieved with 10 μ M of Gd-loaded cHANPs suspension, 
while 100 μ M of Gd-DTPA free in solution is required to achieve a comparable T1. Indeed, the relaxation time 
reported for cHANPs is achieved with a concentration about 10 times lower than that of the free Gd-DTPA. The 
value related to the unloaded cHANPs is also reported, proving that the nanoparticles do not contribute them-
selves to the relaxivity (Fig. 3).
As well-known53, the relaxivity is defined as the rate of change in relaxation times of the water protons per 
mM concentration of metal ions. Larger is the relaxivity of a given CA and larger is the induced spin-lattice relax-
ation time T1 and spin-spin relaxation time T2 shortening. In the presence of CAs, T1 and T2 may be shortened 
considerably. However, an increase in contrast agent concentration provides an increase in signal intensity due to 
the effect on T1 until a certain optimal concentration is reached while further increase in concentration reduces 
the signal because of a broad effect on T2, producing as net result a non-linear relation. This peculiar behaviour 
dictates their use in clinical practice, preferring contrast agents that have a relatively greater effect on T1 than on 
T2 and reveals the enormous advantage of manipulating clinical relevant contrast agents with enhanced MRI 
sensitivity. The relaxation times of the selected cHANPs samples remain unchanged at standard physiological 
conditions for at least 5 days after sample preparation, ensuring no leakage of Gd-DTPA from the cHANPs during 
MRI acquisitions.
Discussion
To date, Gadolinium chelates are the most used in the clinical MRI. Every year, more than 10 million of MRI scans 
are performed with CAs, because of their relatively high stability and inertness in the body even if they still suffer 
from tissue specificity and exhibit low relaxivity54. Several strategies have been investigated to develop better CAs 
with high relaxivity, low toxicity, and tumor specificity through the design and development of several classes of 
Figure 3. In vitro relaxation time distribution. Relaxation time distribution reported for: Gd-DTPA in water 
solution at ( ) 10 μ M, ( ) 60 μ M and ( ) 100 μ M; un-loaded cHANPs ( ); loaded cHANPs at 
standard conditions obtained using ( ) 4% v/v DVS in the side channels, at pH 12.3, reported at 12 μ M of Gd-
DTPA, ( ) 0.8% v/v DVS and Cspan80 0.5% v/v in the middle channel, reported at Gd-DTPA of 10 μ M.
www.nature.com/scientificreports/
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Gd-based MRI contrast agents (CAs) for tumor imaging. However, the exploitation of microfluidics to produce 
hydrogel nanostructures with increased MR performances is still missing.
In this work, we have coupled a flow focused nanoprecipitation to an efficient crosslinking reaction based on 
Divinyl Sulfone (DVS) to entrap the relevant clinical Gd-DTPA in crosslinked Hyaluronic Acid Nanoparticles 
(cHANPs) able to increase its relaxometric properties without the chemical modification of the chelate (Fig. 1).
Typically the microfluidics enables a fast mixing in the microchannels promoting the formation of nano-
materials at laminar flow condition51. In our system, we have individuated a threshold value FR2 of 0.3 below 
which it is possible to obtain more monodisperse and stable nanoparticles as low as 100 nm than the ones pro-
duced by similar bulk and microfluidic approaches55 (Supplementary Figures S1–S3). Furthermore, this threshold 
value is valid for high molecular weight polymers and at several polymer concentrations and different solvent/
non-solvent couples. Our Microfluidic Flow-Focused nanoprecipitation approach has the potential advantage of 
being able to generate a wider range of slot sizes of hydrogel structure while maintaining monodispersity com-
pared to similar bulk systems27. Furthermore, the flexibility of the microfluidic process allows the tuning of the 
nanoparticles’ size for a specific disease through changes of the hydrodynamic boundary conditions.
When Gd-DTPA is added to the polymer solution, a significant flow instability is suddenly detected even at a 
low concentration while no effect is detected even at high GdCl3 concentration (Supplementary Figure S4). We 
believe that the Gadolinium complex acts probably as a salt compound, increasing the hydrogel strength signifi-
cantly. A possible explanation can be that the electrostatic repulsion resulting from the charged groups on poly-
mer chains is suppressed by the accumulation of counterions due to the metal complex56. Furthermore, starting 
from the considerations reported by Gouin et al.57 about the interaction between DTPA and HA, we hypothesize 
that Gd-chelate modifies the affinity of the polymer solution shifting the supersaturation to a low degree and 
leads to a slow heterogeneous nucleation followed by the growth of produced nuclei into large or aggregated 
particles. These specific interactions induce flow perturbation, causing an uncontrolled size variation and for-
mation of aggregated morphologies. A qualitative evaluation of nucleation and growth by diffusion is extensively 
discussed, and related images are reported in the Supplementary Figure S8a–c, where a comparison between the 
traditional16 and microfluidic nanoprecipitation has been carried out to interpret the Gd-DTPA interference and 
to explain the design of the rational strategies that could systematically ensure the entrapment of Gd-DTPA and 
the control of its relaxometric properties.
In particular, for the first strategy, the optimization of the flow-focusing pattern is found to be strongly 
dependent on the hydrophobicity and hydrophilicity of the surfactants (further results are reported in the 
Supplementary Information). However, the main outcome of this approach is the increase of the loading capabil-
ity that can be attributed to the repulsion between surfactant and water phase. Indeed, results clearly demonstrate 
that the retaining of the Gd-CAs is improved by the hydrophobic nature of the surfactant that increases the 
interface viscosity and prevents Gd-DTPA diffusion towards the external non-solvent phases. This behaviour is 
also explained by the higher molecular weight of the CAs, whose extraction, in these conditions, is less favoured 
compared to the small water molecules. These findings are of crucial importance because the use of a surfactant 
is very easy to enforce compared to other alternatives, such as the use of a co-solvent, reduced concentration or 
addition of reacting components that could interfere with the reaction yield and contaminate samples.
Later, the macrocyclic molecules have been firmly entrapped within the hydrogel matrix, using a crosslinking 
reaction simultaneously occurring with the nanoprecipitation (Fig. 2). Investigations related to the addition of the 
DVS in the middle channels or into the side channels have attributed to the hydrogel nanoparticles some peculiar 
properties responsible for the modulation of the release behaviour and swelling properties.
In vitro MRI results (Fig. 3) proved that using our flexible platform it is possible to take advantages from the 
strong interference detected by the presence of Gd-DTPA producing Gd-entrapped nanoparticles with enhanced 
MRI properties. This observation is crucial to lead potentially to a significant reduction of administration dosage 
on clinical usage of T1 contrast agents and to gain advantages in the imaging modalities based on nanotechnolo-
gies. Indeed, the nanoparticles are widely used for the improvement of imaging techniques and all the tunability 
features reported for our system can potentially reduce limitation linked to a fast clearance from the bloodstream 
and low detection due to the dependence on the concentration2.
The proposed approaches aim to overcome some drawbacks of the traditional procedures for the produc-
tion of nanoparticles such as high polydispersity, expensive and time-consuming purification/recovery steps58. 
Furthermore, results present the effective strategy to dose all species and to control properly the entrapment of 
CAs within the hydrogel nanostructures that influences MRI performances in the signal intensity and, potentially, 
the tissue specificity (Fig. 3).
Conclusions
Crosslinked Hyaluronic Acid Nanoparticles (cHANPs) to be applied in MRI field have been developed and 
loaded with a clinically relevant Gd-CA, Gd-DTPA. cHANPs performances have been assessed in terms of longi-
tudinal relaxation rates as a function of the crosslinking degree and loading conditions.
For the first time, an interference of the Gd-DTPA in nanoprecipitation mechanism is reported which has 
added some significant advances in the basic knowledge of the interactions between Gd chelates and hydrogel 
matrix.
We have demonstrated that, through our microfluidic strategies, it is possible to take advantages from the 
observed interference between HA and Gd-DTPA promoting an enhancement of the relaxometric properties 
of the Gd-DTPA loaded in cHANPs without chemically modifying the approved Gd-metal chelate. This micro-
fluidic system is also proposed to overcome some drawbacks of the traditional procedures for the production of 
completely biocompatible and injectable hydrogel nanoparticles under 100 nm with well-defined physicochem-
ical diagnostic properties. The designed strategies have allowed a fine control of the nanoparticle properties, 
such as the monodisperse average size of 40 nm, surface charge and the loading capability of 59%. Additionally, a 
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relaxation rate T1 of 1562 ms is achieved with 10 μ M of Gd-loaded cHANPs while 100 μ M of Gd-DTPA solution is 
required to reach similar T1 (about 1724 ms) as showed in Fig. 3. A controlled degradation and release behaviour 
up to 96 hr under physiological conditions, high encapsulation efficiency of the hydrophilic metal chelate up to 
89% are also reported. Furthermore, easy and full recovery of the cHANPs, without time-consuming and expen-
sive purification steps with respect to the conventional processes, is taken into account.
Results support the concept that the entrapment of the Gd-based CAs within the hydrogel structure can 
enhance relaxivity, thus enable potentially low dosage administration. Therefore, the positive contrast effect is 
preserved, ensuring an improvement of the time window for clinical imaging acquisitions due to the reduction 
of long scan time and rapid renal clearance. Proposed cHANPs could improve the stability and reduce toxicity 
related to the Gd-chelate. Furthermore, the surface charge analysis reports the presence of carboxylic groups that 
can be readily functionalized with targeting moieties, increasing potentially chemical functionalities to impact on 
tissue specificity and integrating additional imaging and therapeutic capabilities.
Materials and Methods
Materials. Sodium Hyaluronate (Mw = 42 kDa) was purchased from Bohus Biotech (Sweden). 
Diethylenetriaminepentaacetic acid gadolinium(III) dihydrogen salt hydrate Gd-DTPA (Mw = 547.57 g/mol; 
Span80; Tween21; Tween85, Divinyl Sulfone (or Vinyl Sulfone) contains < 650 ppm hydroquinone as inhibi-
tor; purity 97%; density 1.117 g/ml at 25 °C (lit.); molecular formula C4H6O2S; Mw = 118.15 mp), Acetone 
(CHROMASOLV, for HPLC, ≥ 99.8%; molecular formula HC3COCH3; Mw = 58.08), Ethanol (ACS reagent, 
≥99.5% (200 proof), absolute; molecular formula CH3CH2OH; Mw = 46.07, Sodium Hydroxide NaOH (ACS 
reagent, ≥ 97.0%, Mw = 40.00), Gadolinium Chloride Solution GdCl3(Mw = 263.61), Sodium Chloride NaCl (ACS 
reagent, ≥ 99.0%, Mw = 58.44) were purchased by Sigma-Aldrich Co. The water, used for synthesis and characteri-
zation, was purified by distillation, deionization, and reserve osmosis (Milli-Q Plus).
Microfluidic set-up for flow-focusing approach. A quartz microfluidic device “X- Junction Chip, 
190 μ m”, purchased from Dolomite Centre Ltd, is used to perform all the experiments. The device has a flow 
focusing geometry with a 90° angle between the inlets to enhance the diffusion process (Figure S1a and b). The 
device is connected to 2.5–5 mL glass syringes (Microsyringes ILS Innovative Labor System) with FEP tubing 
(1/16″ × 0.25 mm) controlled by Nemesys system. Three-way isolation ETFE valves, connecting syringes with the 
microfluidic device, make the automatic fill-in of the syringes feasible, thus allowing a continuous dispensing of 
reagents. The linkage between FEP tubes and device is carried out through a specially designed connection with 
PTFE connectors. The flow-focusing behaviour on the microchannel is observed using an Optical Fluorescence 
Microscope (Olympus IX71) with a 4 or 10 x scanning objective (Fig. 1a).
Production of nanoparticles by nanoprecipitation in microfluidics. Different flow rates were tested, 
and the influence of the Flow Rate Ratio FR2, defined as the ratio of Volume Flow Rate Solvent and Volume Flow 
Rate Non-Solvent, was determined. For the feasibility study, a 5 mL aqueous solution containing HA concentra-
tions ranging from 0.01 to 0.1% wt/v was used to explore the effects of the nanoprecipitation by flow-focusing 
exclusively due to the concentration of the polymer. The initial solution was kept under continuous stirring for at 
least 4 hr and then injected through the middle channel. The flow rate of the middle channel was changed from 
5 to 100 μ L/min. Acetone or Ethanol, used as non-solvent and injected through the side channels, were laterally 
injected to induce nanoprecipitation by a non-solvent extraction. The flow rates of the side channels were ranged 
from 50 μ L/min to 300 μ L/min, increasing each step of 10 μ L/min. Precipitated nanoparticles were collected in 
a Petri glass containing about 25 mL of non-solvent and kept under continuous stirring. Each experiment was 
repeated at least 10 times (see Supplementary Information).
Study of Gd-DTPA interference on the nanoprecipitation. After selecting the best FR2, the influence 
of the Gadolinium on nanoprecipitation was also evaluated. The entrapping of GdCl3 or Gd–DTPA was exploited 
at several weight ratios HA/Gd ranging from 1:0.05 to 1:10, adding the metal complex to the HA aqueous solu-
tion. Loading capability and encapsulation efficiency were calculated by Induced Coupled Plasma (ICP-MS) - 
NexION 350. Nanoparticles were suspended in a solution of deionized (DI) water at a concentration of 150.000 
particles/mL. All data were collected and processed using the Syngistix Nano Application Module. Gd was meas-
ured at m/z 157 using a 100 μ s dwell time with no settling time.
Preparation of crosslinked Hyaluronic Acid Nanoparticles (cHANPs). In the literature studies, the 
chemical reaction between HA and DVS is performed at high pH values (0.2 M NaOH, 0.1 M NaCl, pH > 13)59–61. 
In our microfluidic system, a study on the reagents was conducted to create, at the nozzle section, sulfonyl 
bis-ethyl linkages between the hydroxyl groups of the polymer chains forming nanoparticles (Fig. 1b). Several 
experiments are carried out to study the effect of NaCl and NaOH to promote the reaction and to reduce suddenly 
growth’s step after the nucleation phase. The crosslinking agent was injected alternatively into the middle channel 
(Fig. 1c) or in the side channels (Fig. 1d) at different concentrations, ranging from 0 to 20% v/v and from 0 to 
8% v/v, respectively. In some strategies, the device is heated at 35 °C through a heat chamber. In our system, the 
occurrence of the solvent extraction produces the dilution of water into the main stream, slightly increasing the 
reaction time. For these reasons, to promote the crosslinking reaction, purification and dialysis in water of the 
collected nanoparticles are performed after 4 hr of continuous stirring.
Effect of the surfactant concentrations and pH conditions on the system parameters. All 
experimental conditions were tested by adding NaOH and NaCl to the HA solution at the concentrations ranging 
from 0.1 M to 0.3 M and 0.02 and 0.2 M, respectively.
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Alternately, three surfactants were tested at different reagent concentrations for all experimented flow rates. 
Tween 85 (ranging from 0.5% v/v to 1% v/v), Tween 21 (ranging from 0.5% v/v to 3% v/v) and Span 80 (ranging 
from 0.5% v/v to 1.5% v/v) were mixed to the non-solvent or to the aqueous solution. Experiments were con-
ducted without the addition of DVS.
Stability and swelling behaviour of the cHANPs. Because of the clinical relevance of Gd-DTPA and, 
on the contrary, the high cytotoxicity of the GdCl3, stability studies were optimized only on Gd-DTPA. The 
Gd-DTPA loaded cHANPs were mixed with 150 μ L of Phosphate Buffered Saline (PBS). The nanoparticles were 
kept under shaking at 150 rpm at 37 °C. The solution was divided into two equal parts and observed at 12, 24, 48, 
96 and 172 hr post incubation. ICP-MS was used to assess a one-half of the solution for the total concentration of 
Gd3+ ions loaded within the nanoparticles. The other half of the solution was filtered using 0.45 μ m filter, and the 
filtrate was analyzed for Gd3+ ions.
In vitro MRI. Empty nanoparticles and nanoparticles containing different concentrations of GdCl3 or 
Gd-DTPA were tested by in vitro MRI and results were compared with Magnevist, Gd-DTPA and GdCl3 in water 
as a control. After vigorous stirring, changes in relaxation time (T1) were evaluated at 1.5 Tesla by Minispec 
Bench Top Relaxometer (Bruker Corporation) by adding 300 μ L of the sample in a glass tube45. The relaxation 
time distribution was obtained by CONTIN Algorithm. The relaxation spectrum was normalized with respect 
to the CONTIN processing parameters. The integral of a peak corresponds therefore to the contribution of the 
species exhibiting this peculiar relaxation to the relaxation time spectrum62. Experiments were repeated at least 
five times.
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